Claims for Patent: 9,770,349
✉ Email this page to a colleague
Summary for Patent: 9,770,349
Title: | Nanoporous stents with enhanced cellular adhesion and reduced neointimal formation |
Abstract: | The present invention relates generally to medical devices containing nanoporous surfaces and methods for making same. More specifically, the invention relates to implantable vascular stents or other biomedical devices having at least one dealloyed nanoporous layer that promotes improved cellular adhesion properties that promote healing and long term biocompatibility. In the case of stents, the nanoporous layer promotes re-endothelialization at sites of stent implantation vasculature, improves overall healing, and reduces inflammation and intimal disease progression. The nanoporous layer may be optionally loaded with one or more therapeutic agent to further improve the function of the implanted stent and further augment clinical efficacy. |
Inventor(s): | Owens; Gary (Earlysville, VA), Lye; Whye-Kei (Charlottesville, VA), Reed; Michael (Charlottesville, VA), Spradlin; Joshua (Charlottesville, VA), Wamhoff; Brian (Charlottesville, VA), Hudson; Matthew (Charlottesville, VA), Looi; Kareen (Charlottesville, VA) |
Assignee: | University of Virginia Patent Foundation (Charlottesville, VA) |
Application Number: | 11/753,134 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 9,770,349 |
Patent Claims: | 1. A stent for insertion into a body, the stent comprising a metal stent having a dealloyed porous surface, wherein the stent with only the porous surface and devoid of a
therapeutic agent exhibits reduced neointimal formation compared to a bare metal stent having the same configuration as the metal stent and lacking the porous surface.
2. The stent for insertion into a body as in claim 1, wherein the porous surface is a nanoporous surface with an average pore diameter of less than 200 nm. 3. The stent for insertion into a body as in claim 1, wherein the dealloyed surface is a nanoporous surface with an average pore diameter of less than 200 nm. 4. The stent for insertion into a body as in claim 1, wherein the stent is a coronary stent. 5. The stent for insertion into a body as in claim 1, wherein the stent further comprises a biodegradable coating bonded to the porous surface. 6. The stent for insertion into a body as in claim 1, wherein the stent exhibits a reduced percentage area of stenosis compared to the same bare metal stent lacking the porous surface. 7. The stent for insertion into a body as in claim 1, wherein the stent lacks an elutable therapeutic agent. 8. The stent for insertion into a body as in claim 3, wherein the nanoporous surface contains at least one therapeutic agent. 9. The stent for insertion into a body as in claim 8, wherein the at least one therapeutic agent is selected from a group consisting of: actinomycin-D, batimistat, c-myc antisense, dexamethasone, paclitaxel, taxanes, sirolimus, tacrolimus, everolimus, unfractionated heparin, low-molecular weight heparin, enoxaprin, bivalirudin, tyrosine kinase inhibitors, imatinib mesylate, wortmannin, PDGF inhibitors, AG1295 (6,7-Dimethyl-2-phenylquinoxaline), rho kinase inhibitors, Y27632 ((+)-(R)-trans-4-(1-aminoethyl)-N-(4-pyridyl)cyclohexanecarboxamide dihydrochloride), calcium channel blockers, sphingosine phosphate inhibitors, amlodipine, nifedipine, ACE inhibitors, synthetic polysaccharides, ticlopinin, dipyridamole, clopidogrel, fondaparinux, streptokinase, urokinase, r-urokinase, r-prourokinase, rt-PA, APSAC (anisoylated plasminogen streptokinase activator complex), TNK-rt-PA, reteplase, alteplase, monteplase, lanoplase, pamiteplase, staphylokinase, abciximab, tirofiban, orbofiban, xemilofiban, sibrafiban, roxifiban, ABT-578, CCI-779, biolimus-A9, temsirolimus, anti-CD34 antibodies, mycophenolic acid, Vitamin E, omega-3 fatty acids, tempamine, docetaxel, an agent for altering cytochrome P450 function, cyclosporine, an azole antifungal agent, itraconazole, ketoconazole, a macrolide antibiotic, clarithromycin, erythromycin, troleandomycin, an non-nucleoside reverse transcriptase inhibitor, delavirdine, a protease inhibitor, indinavir, ritonavir, saquinavir, ritonavir, grapefruit juice extract, mifepristone, nefazodone, an anti-restenosis agent, an anti-thrombogenic agent, an antibiotic, an anti-platelet agent, an anti-clotting agent, an anti-inflammatory agent, an anti-neoplastic agent, a chelating agent, penicillamine, triethylene tetramine dihydrochloride, EDTA, DMSA (succimer), deferoxamine mesylate, a radiocontrast agent, a radio-isotope, a prodrug, antibody fragments, antibodies, live cells, therapeutic drug delivery microspheres, drug delivery microbeads, gene therapy agents, viral vectors and plasmid DNA vectors. 10. The stent for insertion into a body as in claim 2, wherein the average pore diameter is less than about 5 nm. 11. The stent for insertion into a body as in claim 3, wherein the average pore diameter is less than about 5 nm. |
Details for Patent 9,770,349
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Microbix Biosystems Inc. | KINLYTIC | urokinase | For Injection | 021846 | 01/16/1978 | ⤷ Try a Trial | 2022-11-13 |
Genentech, Inc. | ACTIVASE | alteplase | For Injection | 103172 | 11/13/1987 | ⤷ Try a Trial | 2022-11-13 |
Genentech, Inc. | CATHFLO ACTIVASE | alteplase | For Injection | 103172 | 09/04/2001 | ⤷ Try a Trial | 2022-11-13 |
Janssen Biotech, Inc. | REOPRO | abciximab | Injection | 103575 | 12/22/1994 | ⤷ Try a Trial | 2022-11-13 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.